House Democrats are preparing to scrutinize drug pricing as Congress returns to Washington, reviving a long-running debate over what patients pay and why.
Democratic control of Congress is set to alter the committees that steer Medicare, drug pricing and broader health policy, while adding lawmakers with medical and scientific backgrounds.
A recent debate over menopause hormone therapy has renewed a familiar question: does treatment affect dementia risk? Here’s what current evidence can and cannot tell us.
Retirement can bring more freedom, but it may also reduce the daily mental, social and physical activity that helps support brain health. Here’s what the evidence suggests.
House Democrats are signaling an early push on Medicaid and Affordable Care Act subsidies, a move that could affect coverage and out-of-pocket costs for millions of Americans.
Medicare has delayed a major remote patient monitoring overhaul until 2029, setting up a longer fight over how home-based tracking services are delivered, staffed, and paid for.
Biomarker testing is moving Alzheimer’s disease earlier in the timeline, sometimes before symptoms appear. That may help with planning and research, but it can also create uncertainty and emotional strain.
A late-stage trial of pelacarsen lowered lipoprotein(a) by a large amount, but it did not reduce major cardiovascular events. Here’s what that means for heart-risk research.
New research presented at an American Heart Association meeting suggests lower blood-pressure goals may help some people after stroke, while benefits were not seen in a diabetes trial.
Daily Health View publishes educational content about health and wellness. When appropriate, articles include scientific references and sources from health organizations. This content is informational and does not replace evaluation by a healthcare professional.